Nuvectis Pharma (NVCT) Cash & Equivalents (2021 - 2026)
Nuvectis Pharma (NVCT) posted Cash & Equivalents of $25.1 million for Q1 2026, down 20.65% sequentially from $31.6 million in Q4 2025, and down 16.05% YoY from $29.9 million in Q1 2025.
Nuvectis Pharma (NVCT) Cash & Equivalents (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Cash & Equivalents for 6 years, with the latest figure at $25.1 million in Q1 2026.
- Quarterly Cash & Equivalents fell 16.05% year-over-year to $25.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.1 million (down 16.05% YoY) and the FY2025 annual result came in at $31.6 million, up 70.69% from the prior year.
- Cash & Equivalents declined to $25.1 million in Q1 2026 per NVCT's latest filing, from $31.6 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $35.4 million in Q3 2025 and troughed at $13.6 million in Q2 2022.
- A 5-year average of $22.3 million and a median of $20.8 million in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents declined 26.36% in 2024, then soared 106.43% in 2025.
- Over 5 years, Cash & Equivalents stood at $23.6 million in 2022, then slipped by 18.96% to $19.1 million in 2023, then decreased by 3.1% to $18.5 million in 2024, then jumped by 70.69% to $31.6 million in 2025, then retreated by 20.65% to $25.1 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $25.1 million, $31.6 million, and $35.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 22.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.20 Mn |
| Mar 31, 2026 | 25.10 Mn |
| Dec 31, 2025 | 31.63 Mn |
| Sep 30, 2025 | 35.44 Mn |
| Jun 30, 2025 | 26.79 Mn |
| Mar 31, 2025 | 29.90 Mn |
| Dec 31, 2024 | 18.53 Mn |
| Sep 30, 2024 | 17.17 Mn |
| Jun 30, 2024 | 18.12 Mn |
| Mar 31, 2024 | 19.50 Mn |
| Dec 31, 2023 | 19.13 Mn |
| Sep 30, 2023 | 22.10 Mn |
| Jun 30, 2023 | 24.60 Mn |
| Mar 31, 2023 | 15.50 Mn |
| Sep 30, 2022 | 23.60 Mn |
| Jun 30, 2022 | 13.60 Mn |
| Mar 31, 2022 | 16.70 Mn |
| Dec 31, 2021 | 5.74 Mn |